Media stories about Adverum Biotechnologies (NASDAQ:ADVM) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adverum Biotechnologies earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.1161193248792 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

A number of research firms recently issued reports on ADVM. ValuEngine cut Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 9th. Chardan Capital reissued a “hold” rating on shares of Adverum Biotechnologies in a research note on Tuesday, December 19th. Finally, Zacks Investment Research raised Adverum Biotechnologies from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th.

Shares of Adverum Biotechnologies (ADVM) opened at $7.05 on Monday. Adverum Biotechnologies has a 52 week low of $2.40 and a 52 week high of $8.59. The stock has a market capitalization of $369.46, a P/E ratio of -4.67 and a beta of 3.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.

Insider Buying and Selling by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with's FREE daily email newsletter.